Article Text

PDF
SAT0427 Asas health index: validity and reliability in argentinean patients with spondyloarthritis
  1. VM Duarte1,
  2. U Kiltz2,
  3. V Navarro-Compán3,
  4. N Lloves1,
  5. G Crespo Amaya1,
  6. L Ferreyra4,
  7. C Orozco5,
  8. EE Schneeberger5,
  9. H Maldonado Ficco6,
  10. D Baenas7,
  11. F Colombres8,
  12. M Mamani1,
  13. JA Maldonado Cocco9,
  14. E Soriano4
  1. 1Hospital B. Rivadavia, Buenos Aires, Argentina
  2. 2Rheumazentrum Ruhrgebiet, Herne, Germany
  3. 3Hospital la Paz, IdiPaz, Madrid, Spain
  4. 4Hospital Italiano de Buenos Aires
  5. 5Instituto de Rehabilitaciόn Psicofísica (IREP), Buenos Aires
  6. 6Hospital San Antonio de Padúa, Río Cuarto
  7. 7Hospital Privado de Cόrdoba, Cόrdoba
  8. 8Hospital de Clínicas Dr. Avellaneda, Tucumán
  9. 9Consulting Profesor of Rheumatology, University of Buenos Aires, Buenos Aires, Argentina

Abstract

Objectives The aim of the study was to translate and validate the ASAS Health Index (ASAS-HI) for Argentinean patients with spondyloarthritis.

Methods Translation was done using a forward-backward procedure and qualitative interview were done with the translation. Patients fulfilling ASAS classification criteria for either axial (axSpA) or periphereal SpA (pSpA) were included to test psychometric properties. Test-retest reliability was assessed by intraclass correlation coefficient (ICC) in patients without treatment changes (stable disease state). In patients who required therapeutic modifications due to changes of disease activity, responsiveness was evaluated using a standardized response mean (SRM). Construct validity against other health outcomes was evaluated by Spearman correlation. Internal consistency (Cronbach-alfa) and discriminative ability between ASAS-HI and ASDAS were assessed.

Results Translation into Argentinean Spanish was accepted with minor changes. Fifty two patients were recruited [65% male, mean (SD) age 39. 5 (12.5) years and median (IQR) disease duration 72 (45–138) months]. Most of the patients had axSpA diagnosis (AS: 26, nr-axSpA: 18) while the rest had pSpA (8). The total score of the ASAS-HI was 7.4 (SD: 4.4), BASDAI: 4.4 (SD: 2.7), BASFI: 4.0 (SD: 3.1), ASDAS-CRP: 2.4 (SD: 0.9). Test-retest reliability (n: 20) was good ICC: 0.88 (95%IC 0.76 to 0.98). Sensitivity to change was tested in 13 patients and SMR was -0.61 for those patients receiving TNF inhibitors (n: 11). Convergent validity ranged as hypothesized with Spearman correlations from low (age: 0.27) to good (pain: 0.65), (table 1). The ASAS-HI discriminated well between patients with different stages of disease activity and function irrespective of the measure applied (ASDAS, BASDAI and BASFI) (table 2). The internal consistency according to Cronbach's alfa was 0.81.

Table 1.

Spearmen correlation coefficient

Table 2.

ASDAS Status Groups

Conclusions The Argentinean version of the ASAS-HI was comprehensive and reliable by patients with SpA. The ASAS-HI is a valid tool for assessing overall functioning and health in spondyloarthritis.

References

  1. The ASAS Health Index (ASAS HI)a new tool to assess the health status of patients with spondyloarthritis, Clin Exp Rheumatol 2014;32:S105-S108.

References

Disclosure of Interest V. Duarte Employee of: Novartis Argentina, U. Kiltz: None declared, V. Navarro-Compán: None declared, N. Lloves: None declared, G. Crespo Amaya: None declared, L. Ferreyra: None declared, C. Orozco: None declared, E. Schneeberger: None declared, H. Maldonado Ficco: None declared, D. Baenas: None declared, F. Colombres: None declared, M. Mamani: None declared, J. Maldonado Cocco: None declared, E. Soriano: None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.